Minoryx Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
32
- Latest Deal Type
-
2ndary - Private
- Investors
-
12
Minoryx General Information
Description
Operator of a biotechnology platform intended to provide treatments for life-threatening rare diseases. The company's platform develops therapies focused on a group of diseases of genetic origin with unmet medical needs and discovers a new generation of pharmacological chaperones to restore protein functionality, enabling patients with therapy for the suffering of orphan diseases.
Contact Information
Website
www.minoryx.comCorporate Office
- Avenida Ernest Lluch 32
- 08302 Barcelona
- Spain
Corporate Office
- Avenida Ernest Lluch 32
- 08302 Barcelona
- Spain
Minoryx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 10. Later Stage VC (Series C) | 31-May-2022 | Completed | Generating Revenue | |||
| 9. Debt - General | 16-Oct-2020 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series B) | 20-May-2020 | Completed | Generating Revenue | |||
| 7. Grant | 09-Apr-2018 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series A) | 25-Jul-2017 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 15-Feb-2017 | Completed | Generating Revenue | |||
| 4. Seed Round | 23-Dec-2014 | Completed | Generating Revenue | |||
| 3. Grant | 06-Dec-2013 | $6.76K | $2.07M | Completed | Generating Revenue | |
| 2. Seed Round | 02-Apr-2013 | $2.07M | $2.07M | Completed | Generating Revenue |
Minoryx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 31,735 | $5.434702 | $192.72 | $192.72 | $192.72 | 16.65% | ||
| Ordinary | 12,441 | $5.434702 | $205.31 | $205.31 | $205.31 | 6.53% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Minoryx Comparisons
Industry
Financing
Details
Minoryx Competitors (106)
One of Minoryx’s 106 competitors is Maze Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Maze Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Immusoft | Venture Capital-Backed | Seattle, WA | ||||
| Lexeo Therapeutics | Formerly VC-backed | New York, NY | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom |
Minoryx Patents
Minoryx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024268104-A1 | Polymorphic forms and formulations of leriglitazone | Pending | 09-May-2023 | ||
| EP-4709476-A2 | Polymorphic forms and formulations of leriglitazone | Pending | 09-May-2023 | ||
| US-20260306468-A1 | Polymorphic forms and formulations of leriglitazone | Pending | 09-May-2023 | ||
| WO-2024231881-A2 | Polymorphic forms and formulations of leriglitazone | Inactive | 09-May-2023 | ||
| WO-2024231881-A3 | Polymorphic forms and formulations of leriglitazone | Inactive | 09-May-2023 | A61K47/10 |
Minoryx Signals
Minoryx Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CDTI Innvierte | Government | Minority | ||
| Columbus Venture Partners | Venture Capital | Minority | ||
| Eurazeo | Asset Manager | Minority | ||
| Carbon ( Belgium ) | Venture Capital | Minority | ||
| Fund+ | Venture Capital | Minority |
Minoryx FAQs
-
When was Minoryx founded?
Minoryx was founded in 2011.
-
Where is Minoryx headquartered?
Minoryx is headquartered in Barcelona, Spain.
-
What is the size of Minoryx?
Minoryx has 32 total employees.
-
What industry is Minoryx in?
Minoryx’s primary industry is Drug Discovery.
-
Is Minoryx a private or public company?
Minoryx is a Private company.
-
What is Minoryx’s current revenue?
The current revenue for Minoryx is .
-
How much funding has Minoryx raised over time?
Minoryx has raised $140M.
-
Who are Minoryx’s investors?
CDTI Innvierte, Columbus Venture Partners, Eurazeo, Carbon ( Belgium ), and Fund+ are 5 of 12 investors who have invested in Minoryx.
-
Who are Minoryx’s competitors?
Maze Therapeutics, Immusoft, Lexeo Therapeutics, Aro Biotherapeutics, and Orchard Therapeutics are some of the 106 competitors of Minoryx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process